Search

Roche Holding AG

Open

BrancheGesundheitswesen

284.2 -3.79

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

283.2

Max

298

Schlüsselkennzahlen

By Trading Economics

Einkommen

6.3B

Verkäufe

31B

KGV

Branchendurchschnitt

29.748

63.778

Dividendenrendite

3.1

Gewinnspanne

20.347

Angestellte

103,249

EBITDA

11B

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.10%

2.39%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

233B

Vorheriger Eröffnungskurs

287.99

Vorheriger Schlusskurs

284.2

Nachrichtenstimmung

By Acuity

18%

82%

32 / 386 Ranking in Healthcare

Roche Holding AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. März 2025, 09:23 UTC

Wichtige Markttreiber

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

30. Jan. 2025, 09:36 UTC

Ergebnisse

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

30. Jan. 2025, 06:32 UTC

Ergebnisse

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

3. Apr. 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3. Apr. 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31. März 2025, 09:31 UTC

Heiße Aktien

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

13. März 2025, 07:46 UTC

Market Talk

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

12. März 2025, 16:34 UTC

Top News

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12. März 2025, 08:51 UTC

Market Talk

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

12. März 2025, 08:18 UTC

Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

13. Feb. 2025, 11:43 UTC

Market Talk

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

30. Jan. 2025, 07:56 UTC

Market Talk
Ergebnisse

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

30. Jan. 2025, 06:04 UTC

Ergebnisse

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

30. Jan. 2025, 06:04 UTC

Ergebnisse

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

30. Jan. 2025, 06:04 UTC

Ergebnisse

Roche Issues 2025 View

30. Jan. 2025, 06:03 UTC

Ergebnisse

Roche Raises Dividend to CHF9.70 Vs CHF9.60

30. Jan. 2025, 06:03 UTC

Ergebnisse

Roche 2024 Core Operating Profit CHF20.82B

30. Jan. 2025, 06:03 UTC

Ergebnisse

Roche 2024 Net Pft CHF9.19B

30. Jan. 2025, 06:02 UTC

Ergebnisse

Analysts Saw 2024 Core EPS at CHF18.59

30. Jan. 2025, 06:02 UTC

Ergebnisse

Roche 2024 Core EPS CHF18.80

30. Jan. 2025, 06:02 UTC

Ergebnisse

Roche 2024 Sales EUR60.50B

30. Jan. 2025, 06:02 UTC

Ergebnisse

Analysts Saw Roche 2024 Revenue at CHF60.41B

30. Jan. 2025, 06:01 UTC

Ergebnisse

Roche 2024 Sales CHFB

28. Jan. 2025, 10:30 UTC

Top News

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

28. Jan. 2025, 07:24 UTC

Market Talk

Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk

15. Jan. 2025, 10:22 UTC

Market Talk

Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk

8. Jan. 2025, 06:15 UTC

Akquisitionen, Fusionen, Übernahmen

Roche: 66.11% of Poseida's Shares Were Validly Tendered in Offer

8. Jan. 2025, 06:12 UTC

Akquisitionen, Fusionen, Übernahmen

Roche Intends to Complete Acquisition of Poseida Therapeutics Later Wednesday

16. Dez. 2024, 22:03 UTC

Top News

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13. Dez. 2024, 16:36 UTC

Market Talk

Swiss Equities an Overweight Pick Next Year -- Market Talk

Roche Holding AG Prognose

Stimmung

By Acuity

32 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.